Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 567

1.

Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson's disease.

Bose A, Beal MF.

Eur J Neurosci. 2018 Nov 8. doi: 10.1111/ejn.14264. [Epub ahead of print]

PMID:
30408242
2.

Aberrant regulation of the GSK-3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy.

Ranea-Robles P, Launay N, Ruiz M, Calingasan NY, Dumont M, Naudí A, Portero-Otín M, Pamplona R, Ferrer I, Beal MF, Fourcade S, Pujol A.

EMBO Mol Med. 2018 Aug;10(8). pii: e8604. doi: 10.15252/emmm.201708604.

3.

Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy.

Tapias V, Jainuddin S, Ahuja M, Stack C, Elipenahli C, Vignisse J, Gerges M, Starkova N, Xu H, Starkov AA, Bettendorff L, Hushpulian DM, Smirnova NA, Gazaryan IG, Kaidery NA, Wakade S, Calingasan NY, Thomas B, Gibson GE, Dumont M, Beal MF.

Hum Mol Genet. 2018 Aug 15;27(16):2874-2892. doi: 10.1093/hmg/ddy201.

4.

Rewiring of Glutamine Metabolism Is a Bioenergetic Adaptation of Human Cells with Mitochondrial DNA Mutations.

Chen Q, Kirk K, Shurubor YI, Zhao D, Arreguin AJ, Shahi I, Valsecchi F, Primiano G, Calder EL, Carelli V, Denton TT, Beal MF, Gross SS, Manfredi G, D'Aurelio M.

Cell Metab. 2018 May 1;27(5):1007-1025.e5. doi: 10.1016/j.cmet.2018.03.002. Epub 2018 Apr 12.

PMID:
29657030
5.

Determination of Coenzyme A and Acetyl-Coenzyme A in Biological Samples Using HPLC with UV Detection.

Shurubor YI, D'Aurelio M, Clark-Matott J, Isakova EP, Deryabina YI, Beal MF, Cooper AJL, Krasnikov BF.

Molecules. 2017 Aug 23;22(9). pii: E1388. doi: 10.3390/molecules22091388.

6.

Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.

Chandra A, Sharma A, Calingasan NY, White JM, Shurubor Y, Yang XW, Beal MF, Johri A.

Hum Mol Genet. 2016 Jun 1;25(11):2269-2282. Epub 2016 Mar 22.

7.

Reductions in the mitochondrial enzyme α-ketoglutarate dehydrogenase complex in neurodegenerative disease - beneficial or detrimental?

Chen H, Denton TT, Xu H, Calingasan N, Beal MF, Gibson GE.

J Neurochem. 2016 Dec;139(5):823-838. doi: 10.1111/jnc.13836.

8.

Mitochondrial dysfunction in Parkinson's disease.

Bose A, Beal MF.

J Neurochem. 2016 Oct;139 Suppl 1:216-231. doi: 10.1111/jnc.13731. Epub 2016 Aug 21. Review.

9.

Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.

Ahuja M, Ammal Kaidery N, Yang L, Calingasan N, Smirnova N, Gaisin A, Gaisina IN, Gazaryan I, Hushpulian DM, Kaddour-Djebbar I, Bollag WB, Morgan JC, Ratan RR, Starkov AA, Beal MF, Thomas B.

J Neurosci. 2016 Jun 8;36(23):6332-51. doi: 10.1523/JNEUROSCI.0426-16.2016.

10.

Simultaneous determination of tricarboxylic acid cycle metabolites by high-performance liquid chromatography with ultraviolet detection.

Shurubor YI, Cooper AJ, Isakova EP, Deryabina YI, Beal MF, Krasnikov BF.

Anal Biochem. 2016 Jun 15;503:8-10. doi: 10.1016/j.ab.2016.03.004. Epub 2016 Mar 19.

PMID:
27001310
11.

Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo.

Esmaeili MA, Yadav S, Gupta RK, Waggoner GR, Deloach A, Calingasan NY, Beal MF, Kiaei M.

Hum Mol Genet. 2016 Jan 15;25(2):317-27. doi: 10.1093/hmg/ddv477. Epub 2015 Nov 24.

12.

HPLC determination of α-ketoglutaramate [5-amino-2,5-dioxopentanoate] in biological samples.

Shurubor YI, Cooper AJ, Isakova EP, Deryabina YI, Beal MF, Krasnikov BF.

Anal Biochem. 2016 Feb 1;494:52-4. doi: 10.1016/j.ab.2015.11.003. Epub 2015 Nov 11.

PMID:
26576832
13.

Metabolomic analysis of exercise effects in the POLG mitochondrial DNA mutator mouse brain.

Clark-Matott J, Saleem A, Dai Y, Shurubor Y, Ma X, Safdar A, Beal MF, Tarnopolsky M, Simon DK.

Neurobiol Aging. 2015 Nov;36(11):2972-2983. doi: 10.1016/j.neurobiolaging.2015.07.020. Epub 2015 Jul 21.

14.

Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy.

Morató L, Ruiz M, Boada J, Calingasan NY, Galino J, Guilera C, Jové M, Naudí A, Ferrer I, Pamplona R, Serrano M, Portero-Otín M, Beal MF, Fourcade S, Pujol A.

Cell Death Differ. 2015 Nov;22(11):1742-53. doi: 10.1038/cdd.2015.20. Epub 2015 Mar 27.

15.

Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions.

Boussicault L, Hérard AS, Calingasan N, Petit F, Malgorn C, Merienne N, Jan C, Gaillard MC, Lerchundi R, Barros LF, Escartin C, Delzescaux T, Mariani J, Hantraye P, Beal MF, Brouillet E, Véga C, Bonvento G.

J Cereb Blood Flow Metab. 2014 Sep;34(9):1500-10. doi: 10.1038/jcbfm.2014.110. Epub 2014 Jun 18.

16.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
17.

Sex differences in cerebral energy metabolism in Parkinson's disease: a phosphorus magnetic resonance spectroscopic imaging study.

Weiduschat N, Mao X, Beal MF, Nirenberg MJ, Shungu DC, Henchcliffe C.

Parkinsonism Relat Disord. 2014 May;20(5):545-8. doi: 10.1016/j.parkreldis.2014.02.003. Epub 2014 Feb 13.

PMID:
24593902
18.

Prospects for neuroprotective therapies in prodromal Huntington's disease.

Chandra A, Johri A, Beal MF.

Mov Disord. 2014 Mar;29(3):285-93. doi: 10.1002/mds.25835. Epub 2014 Feb 26. Review.

19.

Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity.

Stack C, Jainuddin S, Elipenahli C, Gerges M, Starkova N, Starkov AA, Jové M, Portero-Otin M, Launay N, Pujol A, Kaidery NA, Thomas B, Tampellini D, Beal MF, Dumont M.

Hum Mol Genet. 2014 Jul 15;23(14):3716-32. doi: 10.1093/hmg/ddu080. Epub 2014 Feb 20.

20.

PGC-1α overexpression exacerbates β-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease.

Dumont M, Stack C, Elipenahli C, Jainuddin S, Launay N, Gerges M, Starkova N, Starkov AA, Calingasan NY, Tampellini D, Pujol A, Beal MF.

FASEB J. 2014 Apr;28(4):1745-55. doi: 10.1096/fj.13-236331. Epub 2014 Jan 7.

21.

Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K.

JAMA Neurol. 2014 Feb;71(2):141-50. doi: 10.1001/jamaneurol.2013.5528.

22.

Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease.

Weiduschat N, Mao X, Beal MF, Nirenberg MJ, Shungu DC, Henchcliffe C.

J Neuroimaging. 2015 Jan-Feb;25(1):105-10. doi: 10.1111/jon.12074. Epub 2013 Dec 10.

PMID:
24325203
23.

Coordinate regulation of mature dopaminergic axon morphology by macroautophagy and the PTEN signaling pathway.

Inoue K, Rispoli J, Yang L, Macleod D, Beal MF, Klann E, Abeliovich A.

PLoS Genet. 2013;9(10):e1003845. doi: 10.1371/journal.pgen.1003845. Epub 2013 Oct 3.

24.

Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy.

Morató L, Galino J, Ruiz M, Calingasan NY, Starkov AA, Dumont M, Naudí A, Martínez JJ, Aubourg P, Portero-Otín M, Pamplona R, Galea E, Beal MF, Ferrer I, Fourcade S, Pujol A.

Brain. 2013 Aug;136(Pt 8):2432-43. doi: 10.1093/brain/awt143. Epub 2013 Jun 22.

25.

A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin.

Damiano M, Diguet E, Malgorn C, D'Aurelio M, Galvan L, Petit F, Benhaim L, Guillermier M, Houitte D, Dufour N, Hantraye P, Canals JM, Alberch J, Delzescaux T, Déglon N, Beal MF, Brouillet E.

Hum Mol Genet. 2013 Oct 1;22(19):3869-82. doi: 10.1093/hmg/ddt242. Epub 2013 May 29.

26.

Nitration of Hsp90 induces cell death.

Franco MC, Ye Y, Refakis CA, Feldman JL, Stokes AL, Basso M, Melero Fernández de Mera RM, Sparrow NA, Calingasan NY, Kiaei M, Rhoads TW, Ma TC, Grumet M, Barnes S, Beal MF, Beckman JS, Mehl R, Estévez AG.

Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):E1102-11. doi: 10.1073/pnas.1215177110. Epub 2013 Mar 4.

27.

The negative impact of α-ketoglutarate dehydrogenase complex deficiency on matrix substrate-level phosphorylation.

Kiss G, Konrad C, Doczi J, Starkov AA, Kawamata H, Manfredi G, Zhang SF, Gibson GE, Beal MF, Adam-Vizi V, Chinopoulos C.

FASEB J. 2013 Jun;27(6):2392-406. doi: 10.1096/fj.12-220202. Epub 2013 Mar 8.

28.

Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases.

Chaturvedi RK, Beal MF.

Mol Cell Neurosci. 2013 Jul;55:101-14. doi: 10.1016/j.mcn.2012.11.011. Epub 2012 Dec 5. Review.

PMID:
23220289
29.

Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease.

Yao J, Ho D, Calingasan NY, Pipalia NH, Lin MT, Beal MF.

J Exp Med. 2012 Dec 17;209(13):2501-13. doi: 10.1084/jem.20121239. Epub 2012 Dec 3.

30.

Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice.

Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova N, Calingasan NY, Yang L, Tampellini D, Starkov AA, Chan RB, Di Paolo G, Pujol A, Beal MF.

Hum Mol Genet. 2012 Dec 1;21(23):5091-105. doi: 10.1093/hmg/dds355. Epub 2012 Aug 24.

31.

Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease.

Kaidery NA, Banerjee R, Yang L, Smirnova NA, Hushpulian DM, Liby KT, Williams CR, Yamamoto M, Kensler TW, Ratan RR, Sporn MB, Beal MF, Gazaryan IG, Thomas B.

Antioxid Redox Signal. 2013 Jan 10;18(2):139-57. doi: 10.1089/ars.2011.4491. Epub 2012 Aug 13.

32.

Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease.

Lin MT, Cantuti-Castelvetri I, Zheng K, Jackson KE, Tan YB, Arzberger T, Lees AJ, Betensky RA, Beal MF, Simon DK.

Ann Neurol. 2012 Jun;71(6):850-4. doi: 10.1002/ana.23568.

33.

Mitochondrial dysfunction in neurodegenerative diseases.

Johri A, Beal MF.

J Pharmacol Exp Ther. 2012 Sep;342(3):619-30. doi: 10.1124/jpet.112.192138. Epub 2012 Jun 13. Review.

34.

Huntington's disease.

Bonelli RM, Beal MF.

Handb Clin Neurol. 2012;106:507-26. doi: 10.1016/B978-0-444-52002-9.00030-9. Review. No abstract available.

PMID:
22608641
35.

Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.

Chaturvedi RK, Hennessey T, Johri A, Tiwari SK, Mishra D, Agarwal S, Kim YS, Beal MF.

Hum Mol Genet. 2012 Aug 1;21(15):3474-88. doi: 10.1093/hmg/dds178. Epub 2012 May 15.

36.

Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease.

Gollamudi S, Johri A, Calingasan NY, Yang L, Elemento O, Beal MF.

PLoS One. 2012;7(5):e36191. doi: 10.1371/journal.pone.0036191. Epub 2012 May 1.

37.

Muscling in on PGC-1α for improved quality of life in ALS.

Johri A, Beal MF.

Cell Metab. 2012 May 2;15(5):567-9. doi: 10.1016/j.cmet.2012.04.015.

38.

Impaired mitochondrial function in psychiatric disorders.

Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M, Chen G.

Nat Rev Neurosci. 2012 Apr 18;13(5):293-307. doi: 10.1038/nrn3229. Review.

PMID:
22510887
39.

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

Yerramilli-Rao P, Beal MF, Watanabe D, Kieburtz K, Blieck EA, Kitano M, Hosoe K, Funahashi I, Cudkowicz ME.

Int J Toxicol. 2012 Jan-Feb;31(1):58-69. doi: 10.1177/1091581811425256. Epub 2012 Jan 20.

40.

A neuroprotective role of the human uncoupling protein 2 (hUCP2) in a Drosophila Parkinson's disease model.

Islam R, Yang L, Sah M, Kannan K, Anamani D, Vijayan C, Kwok J, Cantino ME, Beal MF, Fridell YW.

Neurobiol Dis. 2012 Apr;46(1):137-46. doi: 10.1016/j.nbd.2011.12.055. Epub 2012 Jan 13.

PMID:
22266335
41.

Antioxidants in Huntington's disease.

Johri A, Beal MF.

Biochim Biophys Acta. 2012 May;1822(5):664-74. doi: 10.1016/j.bbadis.2011.11.014. Epub 2011 Nov 23. Review.

42.

NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease.

Choi DH, Cristóvão AC, Guhathakurta S, Lee J, Joh TH, Beal MF, Kim YS.

Antioxid Redox Signal. 2012 May 15;16(10):1033-45. doi: 10.1089/ars.2011.3960. Epub 2012 Jan 25.

43.

Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.

Johri A, Calingasan NY, Hennessey TM, Sharma A, Yang L, Wille E, Chandra A, Beal MF.

Hum Mol Genet. 2012 Mar 1;21(5):1124-37. doi: 10.1093/hmg/ddr541. Epub 2011 Nov 17.

44.

Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease.

Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, Yang L, Beal MF, Surmeier DJ, Kordower JH, Tabar V, Studer L.

Nature. 2011 Nov 6;480(7378):547-51. doi: 10.1038/nature10648.

45.

Biomarkers of Parkinson's disease and Dementia with Lewy bodies.

Henchcliffe C, Dodel R, Beal MF.

Prog Neurobiol. 2011 Dec;95(4):601-13. doi: 10.1016/j.pneurobio.2011.09.002. Epub 2011 Sep 19. Review.

PMID:
21983334
46.

Behavioral improvement after chronic administration of coenzyme Q10 in P301S transgenic mice.

Elipenahli C, Stack C, Jainuddin S, Gerges M, Yang L, Starkov A, Beal MF, Dumont M.

J Alzheimers Dis. 2012;28(1):173-82. doi: 10.3233/JAD-2011-111190.

47.

Determination of neurotransmitter levels in models of Parkinson's disease by HPLC-ECD.

Yang L, Beal MF.

Methods Mol Biol. 2011;793:401-15. doi: 10.1007/978-1-61779-328-8_27.

PMID:
21913116
48.

Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease.

Dumont M, Kipiani K, Yu F, Wille E, Katz M, Calingasan NY, Gouras GK, Lin MT, Beal MF.

J Alzheimers Dis. 2011;27(1):211-23. doi: 10.3233/JAD-2011-110209.

49.

Truncated peroxisome proliferator-activated receptor-γ coactivator 1α splice variant is severely altered in Huntington's disease.

Johri A, Starkov AA, Chandra A, Hennessey T, Sharma A, Orobello S, Squitieri F, Yang L, Beal MF.

Neurodegener Dis. 2011;8(6):496-503. doi: 10.1159/000327910. Epub 2011 Jul 15.

50.

Molecular insights into Parkinson's disease.

Thomas B, Beal MF.

F1000 Med Rep. 2011;3:7. doi: 10.3410/M3-7. Epub 2011 Apr 1.

Supplemental Content

Support Center